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SUMMARY 
BACKGROUND 
Neuraminidase inhibitors were widely used during the 2009–10 influenza A H1N1 pandemic, but 
evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual 
participant data to investigate the association between use of neuraminidase inhibitors and mortality in 
patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection.  
METHODS 
We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or 
clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data 
contributors from an earlier systematic review of reported studies addressing the same research 
question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or 
April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 
2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did 
a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor 
treatment and mortality (primary outcome), adjusting for both treatment propensity and potential 
confounders, using generalized linear mixed modelling. We assessed the association with time to 
treatment using time-dependent Cox regression shared frailty modelling.  
FINDINGS 
We included data for 29 234 patients from 78 studies of patients admitted to hospital between Jan 2, 
2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment 
(irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 
0·81; 95% CI 0·70–0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of 
symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41–
0·56; p<0·0001). Early treatment versus no treatment was also associated with a reduction in 
mortality (adjusted OR 0·50; 95% CI 0·37–0·67; p<0·0001). These associations with reduced mortality 
risk were less pronounced and not significant in children. There was an increase in the mortality hazard 
rate with each day’s delay in initiation of treatment up to day 5 as compared with treatment initiated 
within 2 days of symptom onset (adjusted HR 1·23 [95% CI 1·18–1·28]; p<0·0001 for the increasing 
HR with each day’s delay). 
INTERPRETATION 
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We advocate early instigation of neuraminidase inhibitor treatment in adults admitted to hospital with 
suspected or proven influenza infection. 
FUNDING 
F. Hoffmann-La Roche. 
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INTRODUCTION 
The neuraminidase inhibitors, oral oseltamivir and inhaled zanamivir, were the predominant medical 
countermeasure available from emergence of the influenza A H1N1pdm09 virus in early 2009, until 
the first release of monovalent H1N1 vaccines in October, 2009. Prescribing data from seven countries 
(Australia, Canada, France, Germany, Japan, UK, USA) suggest at least 18·3 million individuals 
received oseltamivir between May 1, 2009, and Dec 31, 2009.
1
 Country-specific policies for use of 
neuraminidase inhibitors during the 2009–10 pandemic varied from no use, to targeted use in at-risk 
patients (most countries), to treatment of all patients with clinical illness (UK). Most use of 
neuraminidase inhibitors worldwide was in the form of oseltamivir—eg, 97·5% of neuraminidase 
inhibitors used in the USA.
2
 
There is little prepandemic evidence pertaining to the effectiveness of neuraminidase inhibitors in 
reducing mortality in patients admitted to hospital with influenza; most evidence comes from 
observational studies of treatment of seasonal influenza, often in highly specific groups of patients.
3-9
 
Thus, in 2009–10, neuraminidase inhibitors were used on the basis of rational deduction that they 
would reduce mortality due to influenza A H1N1pdm09 virus infection rather than on strong pre-
existing evidence, although data from treatment of human influenza A H5N1 cases suggested this 
reduction in mortality might be possible.
10, 11
 Japanese clinicians used neuraminidase inhibitors widely 
to treat all people presenting with clinical influenza in 2009–10 and recorded the lowest pandemic 
mortality rate of any developed country.
12-14
 Although a similar treat-all policy existed in the UK in 
2009, uptake of neuraminidase inhibitors in patients admitted to hospital with influenza A H1N1pdm09 
was low.
15
  
Two systematic reviews and meta-analyses have examined the effectiveness of neuraminidase 
inhibitors in reducing mortality due to influenza. Both suggest substantial reductions in mortality by 
two-thirds to three-quarters compared with no treatment.
16, 17
 However, limitations are apparent, such 
as the heterogeneity of studies included and inadequate adjustment for potential confounding. 
Importantly, neither was able to adjust for the likelihood of a patient receiving antiviral treatment 
(propensity)—a crucial consideration when antiviral drugs might have been prioritised towards the 
sickest patients—and neither was able to use a pooled analysis approach with individual participant 
data.
18
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METHODS 
Study design and identification of datasets 
The Post-pandemic Review of anti-Influenza Drug Effectiveness (PRIDE) research consortium was set 
up in October, 2011, and is coordinated by the Health Protection and Influenza Research Group at the 
University of Nottingham, Nottingham, UK. The aim of the collaboration is to do individual participant 
data meta-analyses of the effectiveness of antiviral use on outcomes of public health importance during 
the 2009–10 influenza pandemic.Members of the PRIDE research consortium are listed in appendix pp 
1–6. 
The initial identification of potential data contributors was done on the basis of a systematic search of 
11 databases (date of last search April 19, 2012) for observational studies (case series, case-control, 
and cohort studies) and randomised controlled trials done between March 1, 2009 (Mexico), or April 1, 
2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010), 
assessing the association between neuraminidase inhibitor treatment and clinical outcomes (mortality, 
influenza-related pneumonia, admission to critical care, length of stay in hospital and admission to 
hospital). We searched Ovid Medline (reports from 1996 onwards) and Embase (1980 onwards) using 
a comprehensive search strategy. We also searched CINAHL, CAB Abstracts, ISI Web of Science, 
PubMed, UK PubMed Central, Scopus, WHO regional indexes, LILAC, and J-STAGE databases 
using Boolean logic and core search terms relating to pandemic influenza (including influenza A virus 
OR H1N1 subtype OR swine origin influenza AH1N1 virus) AND exposure of interest—ie, antiviral 
drugs (including neuraminidase inhibitors OR oseltamivir OR zanamivir OR peramivir) AND clinical 
outcome measures (including pneumonia, or critical care/intensive care, or mortality). We identified 
further studies from reference lists of relevant articles and through contact with subject area experts 
(via JSN-V-T). All search results were limited to human beings with no language restrictions. Our 
detailed search strategy is reported elsewhere.
17
 
On the basis of this search, we contacted 401 potential data contributors, identified during the conduct 
of our previously reported systematic review;
17
 these potential contributors included several 
corresponding authors from different papers but potentially related to the same source dataset, as an all-
inclusive approach. We recruited additional centres through our network of global collaborators, 
publicity at conferences attended, and by word-of-mouth. Centres fulfilling the minimum dataset 
requirement (appendix pp 7–8) were eligible for inclusion. We requested data for both laboratory 
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confirmed and clinically diagnosed pandemic influenza A H1N1pdm09 cases, but allowed centres to 
provide individual patient data extending to March 14, 2011 (third pandemic wave cases). Clinically 
diagnosed cases that could not be confirmed by virology were diagnosed on the basis of clinical signs 
and symptoms that, in the opinion of the attending physician, were judged to be representative of 
influenza-like illness, in the absence of any other more likely diagnosis. We deliberately accepted 
diagnoses made on clinical judgment rather than specifying a set of clinical criteria, since case 
definitions of influenza-like illness vary within and between countries. This study was granted 
exemption from full ethical review by the University of Nottingham Medical School Research Ethics 
Committee, provided that each contributing centre held its own institutional review board approval for 
data collection and sharing. 
 
Data standardisation, exposures, outcomes, and covariates 
A common data dictionary was developed and individual datasets standardised according to these 
definitions (appendix pp 9–15) before pooling for analysis. 
The primary outcome variable was mortality, defined as death occurring during admission to hospital 
or individual study follow-up period for the generalised linear mixed regression models and as death 
occurring within 30 days of illness onset in the Cox regression models. Use of neuraminidase inhibitors 
(exposure) was defined and compared as follows: neuraminidase inhibitor treatment (irrespective of 
timing) versus none; early neuraminidase inhibitor treatment (starting treatment ≤2 days after symptom 
onset) versus later (initiation >2 days after symptom onset); early neuraminidase inhibitor treatment 
versus none; and later neuraminidase inhibitor treatment versus none. Additionally, we created a 
continuous exposure variable, representing time (in days) between symptom onset and treatment 
initiation (0 meaning treatment commenced on day of symptom onset). Covariates in the final 
multivariable models were “inpatient treatment with oral or intravenous antibiotics” and “inpatient 
treatment with systemic corticosteroids” prescribed during the admission to hospital for influenza along 
with treatment propensity scores. We were unable to adjust for dose or duration of such treatments 
because of the scarce availability of these data across the individual datasets. 
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Propensity scoring 
We calculated propensity scores for the likelihood of neuraminidase inhibitor treatment for each patient 
within individual datasets using multivariable logistic regression for binary treatment variables and 
generalised propensity score estimation for the continuous time to treatment variable as described by 
Hirano and Imbens.
19
 For each separate study dataset we calculated propensity scores (likelihood of 
treatment) for each of the four main exposure measures: neuraminidase inhibitor at any time 
(yes or no), early versus late neuraminidase inhibitor, early versus no neuraminidase inhibitor, and later 
(>2 days) versus no neuraminidase inhibitor. Covariates were then included as follows, irrespective of 
significance: age, sex, comorbidity (yes or no), a proxy indicator of severe disease (yes or no), which 
were, in order of preference, severe respiratory distress; shortness of breath; unweighted symptom 
score; or, if none of these indicators were available, we used one of the following measures of severity: 
AVPU (alert, voice, pain, unresponsive) mental status examination score, Glasgow Coma Scale score, 
Sequential Organ Failure Assessment score, or CURB-65 (confusion, urea, respiratory rate, blood 
pressure, age ≥65 years) pneumonia severity scores, if these were available, entered as a continuous 
variable. We added the following variables when available to create an extended model, using a 
parsimonious approach that retained only significant covariates in the final model: obesity, smoking, 
pregnancy, asthma, chronic obstructive pulmonary disease, lung disease, heart disease, 
immunosuppression, neurological disease, renal disease, and diabetes. We rejected variables with more 
than 25% missing data. Some variables used for the propensity score calculation, such as comorbidity 
(binary) and illness severity at presentation (binary), were derived at individual study level only and 
were not appropriate for inclusion in the pooled dataset analysis because of the heterogeneity in 
definition of these variables between studies. 
The appropriateness of the propensity derivation models was assessed graphically by comparing the 
distribution of estimated propensity scores across treatment groups for each individual dataset.
20
 
Propensity scores were then categorised into quintiles for each individual dataset. 
 
Statistical analysis 
We used a generalised linear mixed model to account for clustering of effects by study using the 
xtmelogit command in Stata (version 12). We included “study” as a random intercept to account for 
differences in baseline crude mortality rate at each site. We adjusted the model for treatment 
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propensity, inpatient antibiotics, and systemic corticosteroids. We included missing data in covariates 
as a separate dummy category. The overall analysis included patients of all ages with laboratory or 
clinically diagnosed influenza A H1N1pdm09. We did prespecified stratified analyses for adults and 
children (<16 years), pregnant women (irrespective of age), laboratory confirmed influenza A 
H1N1pdm09 cases, and patients admitted to critical care units. Additionally, for a subset of our sample 
for whom exact onset and treatment initiation times were available, we investigated the association 
between time to initiation of antiviral treatment and mortality within 30 days of illness onset using a 
time-dependent Cox regression shared frailty model (to account for clustering by study) adjusted for 
propensity score and inpatient treatment with antibiotics or systemic corticosteroids. Antiviral 
treatment was modelled as a time-dependent covariate to overcome immortal time bias (ie, survivor 
bias). Results from the generalised linear mixed model are expressed as relative risks of mortality using 
odds ratios (ORs) and hazard ratios (HRs) for the Cox regression analysis with 95% CIs. We used Stata 
(version 12) for all analyses.  
The protocol
21
 for this study was registered with the PROSPERO register of systematic reviews, 
number CRD42011001273. 
Role of the funding source  
The funder of the study had no role in the study design, data collection, data analysis, data 
interpretation, writing of the report. The funder has not and will never have access to the data. Each 
collaborator had access to the raw data from his or her centre. SGM, SV, PRM, JL-B, and JSN-V-T 
had access to the pooled dataset. The corresponding author (JSN-V-T) had full access to all the data in 
the study and the final responsibility for the decision to submit for publication. 
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RESULTS 
We received replies from 128 (32%) of 401 centres contacted; of these 77 (60%) confirmed willingness 
to participate and the remainder declined (36 [28%] had no data; three [2%] agreed initially but later 
withdrew because of lack of capacity for data extraction, institutional review board restrictions 
preventing sharing of individual participant data, or failure to obtain government approval for data 
sharing; 12 [9%] had agreed in principle, but were unable to share data within project timescales). No 
data were requested from nor provided by pharmaceutical companies. After exclusion of duplicate 
responses (same source dataset), and addition of three further datasets provided through informal 
contact with domain experts, 80 research groups from 38 countries in six WHO regions contributed 
anonymised data for 168 117 patients, of whom 24 416 had laboratory results indicative of 
noninfluenza A H1N1 disease. Among the remaining 143 701 laboratory confirmed or clinically 
diagnosed (without standard study-wide case definition) influenza A H1N1pdm09 cases, 106 138 were 
outpatients and 2593 had missing information for hospital admission. The remaining 34 970 inpatients 
were eligible for inclusion (figure 1).  
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Figure 1: Study flow diagram 
 
 
  
*47 overlapping data; one onset of illness before March 1, 2009 (Mexico); nine missing data for key variables. 
Mortality data missing, 
n=2,095 
 
401 centres contacted 
34 970 inpatients from 78 centres  
 
324 centres excluded  
273 centres did not respond  
51 declined to participate  
 
3 centres identified by contact 
with experts  
 
168 117 potentially eligible patients 
disclosed by 80 centres  
 
24,416 patients without influenza A 
H1N1pdm09 virus infection  
 
143,701 patients with laboratory 
confirmed or clinically diagnosed 
influenza A H1N1pdm09 virus 
infection  
 
108,731 excluded  
106,138 outpatients (two 
studies of outpatients only 
excluded)  
2593 unknown admission status  
 
5736 patients excluded 
3584 missing data for exposure 
to neuraminidase inhibitors  
2095 missing mortality status  
57 other reasons*  
 
29234 patients from 78 centres 
included in analysis  
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Of the 34 970 inpatients eligible for inclusion, 2095 (6%) had missing information for mortality status, 
and 3584 (10%) for exposure to neuraminidase inhibitors; 57 (<1%) were unsuitable for inclusion for 
other reasons (figure 1). Ultimately, we included 29 234 records from 78 studies (two studies provided 
only outpatient data and were excluded from analysis) of patients admitted to hospital between Jan 2, 
2009, and March 14, 2011: 25 001 (86%) laboratory confirmed; 9218 (32%) children; and 1600 (5%) 
aged 65 years or older. Appendix p 16 show the incidence of cases by month. Full characteristics of the 
pooled dataset are listed in table 1with absolute risks of mortality for various exposure categories and 
subgroups summarised in appendix p 16. Baseline characteristics of each constituent dataset are 
presented in appendix pp 17–21. 
Patients without neuraminidase inhibitor treatment data and therefore excluded from analysis were 
more likely to be older, to have presented to hospital later, less likely to have a laboratory confirmed 
diagnosis, and more likely to be treated with antibiotics than were patients included in the analysis 
(appendix pp 26–27). However, they were less likely to be smokers, obese, or to have an underlying 
comorbidity. Additionally, their hospital stay was shorter, and they were less likely to have severe 
outcomes (admission to critical care unit or death), or influenza-related pneumonia (appendix pp 26–
27). 
 After adjustment for propensity score and corticosteroid and antibiotic treatment, the likelihood of 
mortality in patients treated with a neuraminidase inhibitor was 0·81 (95% CI 0·70–0·93), compared 
with no treatment (table 2). The OR did not change substantially when only laboratory confirmed cases 
were included (adjusted OR 0·82 [95% CI 0·70–0·95]). Similarly, we identified significant 
associations with a reduced mortality risk in adults, pregnant women, and critically ill adult patients 
(table 2). However, there was no significant association between neuraminidase inhibitor treatment and 
mortality in children aged 0–15 years (table 2). Post-hoc analyses restricted to children up to 1 year of 
age and up to 5 years of age did not change this finding (appendix p 27). 
Early neuraminidase inhibitor treatment compared with later treatment initiation was associated with an 
overall significant reduction in mortality risk (adjusted OR 0·48 [95% CI 0·41–0·56]; table 3). The 
ORs remained essentially unchanged when only laboratory confirmed cases were considered, but risk 
reduction was higher in pregnant women (table 3). Notably, there was again no significant association 
between early treatment and mortality in children after adjustment (table 3). 
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Table 1: Characteristics of pooled dataset of 29,234 patients hospitalised with 
A(H1N1)pdm09 virus infection included in mortality analysis  
 
Characteristic (denominator) 
All hospitalised 
patients  
 n (%) 
Deceased  
n (%) 
Survived  
n (%) 
Number of patients† 29,234  (100·0) 2,784 (9·5) 26,450 (90·5) 
Number of male cases (n=29,226)† 14,431 (49·4) 1,433 (51·5) 12,998 (49·1) 
Age: median (IQR) in years (n=29,034)† 26 (11 -  44) 40 (26 - 54) 25 (10 - 42) 
Adults (≥16 years)  
Children (<16 years) 
19,816 (67·8) 
9,218 (31·5) 
2,450 (88·0) 
325 (11·7) 
17,366  (65·7) 
8,893 (33·6) 
Obese‡ (n=22,527)† 2,607 (8·9) 517 (18·6) 2,090 (7·9) 
Smoking (n=19,066)† 2,406 (8·2) 285 (10·2) 2,121 (8·0) 
Pregnant women§ (n=9,513)† 2,166 (22·8) 177 (18·6) 1,989 (23·2) 
WHO Regions (n=29,234)† 
African region 
Region of the Americas 
Eastern Mediterranean Region 
European Region 
South-East Asia Region 
Western Pacific Region 
 
41(0·1) 
14,186 (48·5) 
5,262 (18·0) 
7,272 (24·9) 
210 (0·7) 
2,263 (7·7) 
 
14 (0·5) 
1,477 (53·1) 
518 (18·6) 
680 (24·4) 
14 (0·5) 
81 (2·9) 
 
27 (0·1) 
12,709 (48·1) 
4,744 (17·9) 
6,592 (24·9) 
196 (0·7) 
2,182 (8·3) 
A(H1N1)pdm09 diagnosis (n=29,234)† 
    Laboratory confirmed  
    Clinically diagnosed  
 
25,001 (85·5) 
4,233 (14·5) 
 
2,486 (89·3) 
298 (10·7) 
 
22,515 (85·1) 
3,935 (14·9) 
Comorbidities† ¶ 
Any comorbidity (n=28,672) 
Asthma (n=20,518) 
COPD (n=17,081) 
Other chronic lung disease (n=17,853)  
Heart disease (n=18,419) 
Renal disease (n=19,860) 
Liver disease (n=12,264) 
Cerebrovascular disease (n=9,803) 
Neurological disease (n=13,598) 
Diabetes  (n=24,764) 
Immunosuppression (n=25,268) 
 
11,011 (37·7) 
2,820 (9·7) 
1,012 (3·5) 
2,479 (8·5) 
1,624 (5·6) 
710 (2·4) 
295 (1·0) 
304 (1·0) 
1,013 (3·5) 
2,087 (7·1) 
1,803 (6·2) 
 
1,471 (52·8) 
134 (4·8) 
171 (6·1) 
272 (9·8) 
317 (11·4) 
151 (5·4) 
81 (2·9) 
34 (1·2) 
136 (4·9) 
418 (15·0) 
346 (12·4) 
 
9,540(36·1) 
2,686 (10·2) 
841 (3·2) 
2,207 (8·3) 
1,307 (4·9) 
559 (2·1) 
214 (0·8) 
270 (1·0) 
877 (3·3) 
1,669 (6·3) 
1,457 (5·5) 
Pandemic H1N1 vaccination (n=4,382) †|| 347 (2.3) 27 (1.7) 320 (2.3) 
Time from symptom onset to hospital admission, days, median (IQR) 
(n=23,769)† 
2 (1 – 5) 4 (2 - 6) 2 (1 - 4) 
Antiviral agents used  
   No NAI treatment 
Any NAI   
  Oral oseltamivir  (n=18,803)** 
  Intravenous/inhaled zanamivir   (n=18,803)** 
  Intravenous peramivir (n=18,803)**  
  NAI (regimen unknown) (n= 18,803)** 
   
  NAI and Non-NAI (n=18,803)** 
  NAI combination therapy (n= 18,803)** 
 
  Early NAI (≤2 days of symptom onset) (n=13,254)†** 
  Later NAI  (>2 days after symptom onset)    (n=13,254)†** 
 
10,431 (35·7) 
18,803 (64·3) 
17,309 (92·1) 
435 (2·3) 
49 (0·3) 
1,251 (6·7) 
 
94 (0·5)  
238  (1·3) 
 
5,995 (31·9) 
7,259 (38·6) 
 
959 (34·5) 
1,825 (65·6) 
1,675 (91·8) 
52 (2·9) 
28 (1·5) 
140 (7·7) 
 
18 (1·0) 
69 (3·8) 
 
358 (19·6) 
942 (51·6) 
 
9,472 (35·8) 
16,978 (64·2) 
15,634 (92·1) 
383 (2·3) 
21 (0·1) 
1,111 (6·5) 
 
76 (0·5) 
169 (1·0) 
 
5,637 (33·2) 
6,317 (37·2) 
Time from symptom onset to antiviral treatment, days, median (IQR) 
(n=12,284)† 
3 (1 – 5) 4 (2 - 7) 3 (1 - 5) 
Other in-hospital treatment † 
Antibiotics (n=20,362) 
Corticosteroids  (n= 9,982) 
 
13,230 (45·3) 
2,745 (9·4) 
 
1,096 (39·4) 
453 (16·3) 
 
12,134 (45·9) 
2,292 (8·7) 
Hospital length of stay, days, median (IQR) (n=22,366)† 5 (2 – 9) 7 (2 - 15) 5 (2 - 8) 
Other patient outcomes † 
Influenza-related pneumonia†† (n=16,551) 
Admission to critical care (n=24,435) 
 
7,225 (24·7)  
6,848 (23·4) 
 
1,035 (37·2) 
1,957 (70·3) 
 
6,190 (23·4) 
4,891 (18·5) 
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Data are n (%) or median (IQR). COPD=chronic obstructive pulmonary disease. NAI=neuraminidase inhibitor. 
 *All percentages have been calculated using these denominators unless otherwise specified.  
†Missing data; n shows number of cases with data.  
‡Reported as clinically obese or using WHO definition for obesity (BMI ≥30 kg/m² in adults aged ≥20 years).  
§Proportions were calculated as a percentage of pregnant patients among female patients of reproductive age (13–54 years); the 
broader age range was selected in preference to the WHO definition (15–44 years) after consultation with data contributors to 
reflect the actual fertility experience of the sample.  
¶For definition of comorbidity, see appendix pp 9–11.  
||Denominators for pandemic vaccine based on patients admitted after Oct 1, 2009 (when vaccine potentially available).  
**Percentages calculated as a proportion of the sample receiving NAI therapy.  
††Clinically or radiologically diagnosed pneumonia. 
 
 
Table 2: NAI TREATMENT (AT ANY TIME) VS. NONE 
Subgroups 
Crude analysis Adjusted† analysis 
OR (95% CI) P 
value 
OR (95% CI) P 
value 
Laboratory confirmed or clinically 
diagnosed (all ages); n=29,234 
0·92 (0·81 to 1·05) 0·21 0·81 (0·70 to 0·93) 0·0024 
Laboratory confirmed cases (all ages) ; 
n=25,001 
0·94 (0·81 to 1·09) 0·42 0·82 (0·70 to 0·95) 0·0104 
Adults (16 years and above) ; n=19,816 0·82 (0·70 to 0·95) 0·0071 0·75 (0·64 to 0·87) 0·0002 
Children (below 16 years); n=9,218 1·02 (0·73 to 1·42) 0·90 0·82 (0·58 to 1·17) 0·28 
Pregnant women; n=2,166 0·47 (0·24 to 0·90) 0·0228 0·46 (0·23 to 0·89) 0·0215 
ICU patients 
   Adults (≥16 years);  n=5,103 
  Children (<16 years); n=1,725 
 
0·74 (0·57 to 0·95) 
0·84 (0·52 to 1·37) 
 
0·0187 
0·49 
 
0·72 (0·56 to 0·94) 
0·70 (0·42 to 1·16) 
 
0·0155 
0·17 
†adjusted for treatment propensity (by quintile), corticosteroid use and antibiotic use 
 
 
 
Neuraminidase inhibitor treatment within 2 days of symptom onset compared with none was also 
associated with a significant reduction in mortality in all patients (adjusted OR 0·50 [95% CI 0·37–
0·67]; table 3), with significant risk reductions also noted among laboratory confirmed cases, adults, 
pregnant women, and adult patients admitted to critical care (table 3). However, there was no 
significant association with a lower mortality risk in children aged 0–15 years (table 3). 
With regard to neuraminidase inhibitor treatment started more than 2 days after symptom onset 
compared with none, we identified no significant association with mortality in all patients (adjusted OR 
1·20 [95% CI 0·93–1·54]), nor in laboratory confirmed cases, adults, pregnant women, or children 
(table 4). However, we noted an associated mortality risk reduction of about a third (adjusted OR 0·65 
[95% CI 0·46–0·93]) in adult patients admitted to critical care.  
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Table 3: EARLY NAI TREATMENT (≤2 DAYS AFTER ONSET) VS. LATER (>2 DAYS) OR NONE 
Early treatment vs. Later treatment: 
Subgroups 
Crude analysis Adjusted† analysis 
OR (95% CI) P value OR (95% CI) P value 
Laboratory confirmed or clinically 
diagnosed (all ages); n=13,254 
0·36 (0·31 to 0·41) <0·0001 0·48 (0·41 to 0·56) <0·0001 
Laboratory confirmed cases (all ages) ; 
n=12,992 
0·36 (0·31 to 0·41) <0·0001 0·48 (0·41 to 0·56) <0·0001 
Adults (16 years and above); n=9,270 0·37 (0·32 to 0·44) <0·0001 0·45 (0·38 to 0·54) <0·0001 
Children (below 16 years); n=3,899 0·53 (0·35 to 0·80) 0·0026 0·67 (0·44 to 1·03) 0·07 
Pregnant women ; n= 917 0·20 (0·09 to 0·46) 0·0002 0·27 (0·11 to 0·63) 0·0026 
ICU patients 
     Adults (≥16 years); n=3,385 
    Children (<16 years); n=683 
 
0·64 (0·51 – 0·79) 
1·12 (0·63 to 1·99) 
 
<0·0001 
0·69 
 
0·62 (0·49 to 0·77) 
1·15 (0·64 to 2·06) 
 
<0·0001 
0·64 
Early treatment vs. none: 
Laboratory confirmed or clinically 
diagnosed (all ages); n=16,425 
0·54 (0·40 to 0·72) <0·0001 0·50 (0·37 to 0·67) <0·0001 
 
Laboratory confirmed cases (all ages); 
n= 13,200 
 0·53 (0·39 to 0·71) <0·0001 0·48 (0·36 to 0·66) <0·0001 
Adults (16 years and above) ; n=10,607 0·39 (0·28 to 0·55) <0·0001 0·38 (0·27 to 0·54) <0·0001 
Children (below 16 years); n=5,696 1·08 (0·61 to 1·93) 0·79 0·85 (0·47 to 1·53) 0·59 
Pregnant women, n=1,303 0·16 (0·04 to 0·64) 0·0099 0·16 (0·04 to 0·67) 0·0118 
ICU patients 
    Adults (≥16 years); n=1,608 
    Children (<16 years); n=572 
 
0·30 (0·19 to 0·45) 
0·88 (0·40 to 1·91) 
 
<0·001 
0·74 
 
0·31 (0·20 to 0·47) 
0·76 (0·34 to 1·67) 
 
<0·001 
0·49 
†adjusted for treatment propensity (by quintile), corticosteroid use and antibiotic use 
 
 
Information about exact timing of neuraminidase inhibitor treatment from symptom onset was 
available for 65% (12284 of 18803) of those receiving such treatment. After taking into account 
clustering by study, propensity score quintiles, and inhospital treatment with antibiotics or systemic 
corticosteroids, when antiviral use was modelled as a time-dependent covariate to overcome potential 
immortal time bias (ie, survivor bias), neuraminidase inhibitor treatment was significantly associated 
with decreased hazard rate of mortality over a 30-day follow-up period (adjusted HR 0·51 [95% CI 
0·45–0·58], p<0·0001) as compared with no antiviral treatment. When only treated cases were 
included, there was an increase in the hazard with each day’s delay in initiation of treatment up to day 
5 as compared with treatment initiated within 2 days of symptom onset (adjusted HR 1·23 [95% CI 
1·18–1·28], p<0·0001 for the increasing HR with each day’s delay). The unadjusted and adjusted 
survival curves comparing survival by time to treatment initiation are shown in figure 2 and appendix 
pp 28–29. 
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Table 4: LATER NAI TREATMENT (>2 DAYS) VS. NONE 
Population Subgroups 
Crude analysis Adjusted† analysis 
OR (95% CI) P value OR (95% CI) P value 
Laboratory confirmed or clinically 
diagnosed (all ages); n=17,670 
1·27 (1·00 to 1·61) 0·0497 1·20 (0·93 to 1·54) 0·15 
Laboratory confirmed cases (all ages); 
n=14,409 
1·25 (0·98 to 1·59) 0·07 1·17 (0·92 to 1·51) 0·21 
Adults (16 years and above); n=12,269 1·01 (0·77 to 1·32) 0·94 1·01 (0·76 to 1·33) 0·96 
Children (below 16 years); n=5,282 1·34 (0·78 to 2·31) 0·29 1·29 (0·75 to 2·21) 0·36 
Pregnant women, n=1,302 0·72 (0·26 to 2·01) 0·53 0·70 (0·24 to 2·06) 0·51 
ICU patients 
    Adults (≥16 years); n=2,977 
    Children (<16 years); n=644 
   
0·61 (0·43 to 0·86) 
0·65 (0·32 to 1·36) 
 
0·0045 
0·25 
 
0·65 (0·46 to 0·93) 
0·75 (0·35 to 1·57) 
 
0·0183 
0·44 
†adjusted for treatment propensity quintiles, corticosteroid use and antibiotic use 
 
 
 
Figure 2: Survival by time to treatment 
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Panel: Research in context 
Systematic reviews 
Two systematic reviews and meta-analyses have examined the effectiveness of neuraminidase 
inhibitors in reducing mortality due to influenza. Hsu and colleagues
16
 considered reported 
observational data, mainly for seasonal influenza, and concluded that oral oseltamivir might reduce 
mortality (odds ratio [OR] 0·23 [95% CI 0·13–0·43). In our own systematic review, we included only 
reported data from the 2009–10 influenza A H1N1pandemic (all observational) and showed that early 
neuraminidase inhibitor treatment versus none reduced mortality by two thirds (OR 0·35 [95% CI 
0·18–0·71]).17 We applied search terms relating to pandemic influenza (including “Influenza A Virus” 
OR “H1N1Subtype” OR “swine origin influenza AH1N1 virus”), AND exposure of interest—ie, 
antiviral drugs (including “neuraminidase inhibitors” OR “oseltamivir” OR “zanamivir” OR 
“peramivir”) AND clinical outcome measures (including “pneumonia”, “critical or intensive care”, 
“mortality”) to 11 databases (search range from Jan 1, 2009, to Aug 10, 2010; last search on April 19, 
2012) without imposing language restrictions. Importantly, both studies acknowledged limitations such 
as the heterogeneity of studies included and inadequate adjustment for potential confounding. 
Moreover, neither was able to adjust for the likelihood of a patient receiving antiviral treatment 
(propensity)—a crucial consideration when antiviral drugs might have been prioritised towards the 
sickest patients. 
Interpretation 
By using a meta-analysis of individual patient data, which permits a uniform approach to potential 
confounding and adjustment for treatment propensity, and through the assembly of a very large 
international dataset, our study adds substantially to the evidence that neuraminidase inhibitors 
administered to adults admitted to hospital with influenza A H1N1pdm09 reduced mortality, especially 
when started promptly. Since placebo-controlled randomised controlled trials of neuraminidase 
inhibitors are not ethically feasible during a pandemic, the evidence we have assembled is likely to be 
the best that will be available. The US Centers for Disease Control and Prevention recommend 
neuraminidase inhibitor treatment as early as possible for any patient with confirmed or suspected 
influenza who is hospitalised; has severe, complicated or progressive illness; or is at higher risk for 
influenza complications. 
22
 Neuraminidase inhibitors are also widely prescribed in Japan, but elsewhere 
their use is far less common. Although a similar treat-all policy existed in the UK in 2009, uptake of 
neuraminidase inhibitors inpatients admitted to hospital with influenza A H1N1pdm09 virus was low.
15
 
We advocate early instigation of neuraminidase inhibitor treatment in adults admitted to hospital with 
suspected or proven influenza infection. 
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DISCUSSION 
Our results show that neuraminidase inhibitor treatment was associated with reduced mortality in adult 
patients admitted to hospital with influenza A H1N1pdm09 virus infection. Neuraminidase inhibitor 
treatment of influenza A H1N1pdm09 at any stage of illness compared with none revealed an 
associated reduction in the likelihood of mortality (table 2). We identified an associated likelihood of 
lower mortality when comparing early versus later initiation of treatment and when comparing early 
treatment with none (table 3, panel). Although we included 4233 patients (14%) without laboratory 
confirmed influenza A H1N1pdm09, restriction to laboratory-confirmed cases produced near identical 
estimates, suggesting that the data are not confounded by misclassification bias attributable to other 
causes (tables 2, 3). Additionally, we noted much the same findings in adults, pregnant women, and 
adult patients needing admission to critical care. The finding regarding critical care suggests that 
neuraminidase inhibitors were associated with mortality reduction across the spectrum of severity in 
adult patients admitted to hospital with influenza A H1N1pdm09. These findings accord closely with 
previous studies
16, 17
  but have increased precision and reduced estimates of effectiveness consistent 
with more complete adjustment for confounders and treatment propensity. They are also consistent 
with ecological data. 
23-25
 
We were consistently unable to show any association of neuraminidase inhibitor treatment with 
mortality reduction in children. Possible explanations include lower case fatality proportion in 
paediatric patients (thus reduced statistical power),
26, 27
 higher influenza A H1N1pdm09 viral load in 
children
28
 than adults leading to reduced drug effectiveness, suboptimum dosing in very young 
children,
29
 secondary bacterial infections (eg, methicillin-resistant Staphylococcus aureus), 
confounding by indication
30
 (children might have been more likely to have had antivirals prescribed if 
they had more severe disease or if they failed to respond to other treatments), or a combination of these 
factors. Since it has been suggested that younger children might be admitted with milder disease 
compared with older children and adults (precautionary physician behaviour), that the 
pharmacokinetics and pharmacology of oseltamivir might be different in very young children,
29
 and 
that influenza pathogenesis might differ by age,
31
 we did post-hoc sensitivity analyses separately in 
children up to 1 year of age and up to 5 years of age, but our findings did not change (appendix p 27). 
However, we note that these results contrast with those of Louie and colleagues,
32
 who recently showed 
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a two-thirds reduction in mortality among children treated with neuraminidase inhibitors admitted to 
hospital with influenza (OR 0·36 [95% CI 0·16–0·83]).  
The finding that no treatment was better than late treatment is probably explained by confounding due 
to illness severity at the point of treatment initiation (ie, confounding by indication). Untreated patients 
probably had milder disease and patients treated later in the course of their illness might have had 
delays in hospital admission, delays in diagnosis after admission, or delays in being considered for 
neuraminidase inhibitor treatment (treatment only started once their condition deteriorated), or 
combinations of these factors. We advocate early consideration of a diagnosis of influenza in patients 
admitted to hospital with respiratory infection during periods of known influenza activity, and early 
instigation of neuraminidase inhibitor treatment based on rapid laboratory confirmation or clinical 
suspicion. 
Our analyses examining the effect of later treatment versus none are especially relevant to the 
continued clinical debate about the value of delayed therapy. Combining all subgroups of patients, we 
did not identify any protective association with treatment delayed more than 2 days after symptom 
onset (table 4). This finding could be explained by confounding by indication. However, we noted that 
in adult patients admitted to critical care, delayed treatment was associated with reduced likelihood of 
mortality compared with no treatment (table 4), suggesting that delayed therapy might still be 
worthwhile in severely ill patients; this finding is plausible since, within this subgroup, treated and 
untreated patients (who all needed admission to critical care) are likely to have been more balanced in 
terms of illness severity thereby overcoming confounding by this factor to some extent. Additionally, 
some patients admitted to critical care might have had prolonged influenza A H1N1pdm09 virus 
replication in the lower respiratory tract, which might benefit from later initiation of neuraminidase 
inhibitor treatment. To gain further understanding about overall timing-dependent benefit, we modelled 
time to start of antiviral treatment using a time-dependent Cox regression model, which showed a 
significant detrimental survival benefit associated with delay in treatment beyond 2 days after symptom 
onset (p<0·0001), albeit with overlapping 95% CIs when time to treatment was modelled as a 
categorical variable; the latter finding suggests that potential differences in treatment benefit between 
starting on day 3 after symptom onset through to more than 5 days after symptom onset cannot be 
further clarified through our data. This finding could seem to conflict with the findings in table 4 
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comparing later neuraminidase inhibitor treatment to no neuraminidase inhibitor treatment but is not 
surprising, because by comparing only treated patients in figure 2, we possibly eliminated some of the 
confounding due to indication, which allowed us to identify the potential survival benefits conferred by 
later treatment, albeit detrimental in proportion to treatment delay. 
One of the strengths of this study is the very large number of patients from geographically diverse 
clinical centres and source populations. We made exhaustive efforts to identify suitable datasets from 
around the world, but nevertheless cannot comment on the extent to which bias might have been 
introduced by failing to include centres that did not respond (we cannot say if they had suitable data or 
not), or that declined to share data; in a worst case scenario, it is possible that less than 20% of 
potential sites contributed to this analysis. Furthermore, comparatively few cases were from the WHO 
African (0·1%) and South-East Asia (0·7%) regions, which might limit the extent to which our findings 
can be generalised. 
A clear limitation of our study is that we were unable to adjust specifically for disease severity in our 
multilevel models because of the heterogeneity of severity measures used across individual datasets. 
However, we made every effort to include relevant data including severity measures, within each 
propensity score, but there is still likely to be some residual confounding, particularly due to illness 
severity at presentation. Likewise, we attempted to control for study-level biases, such as treatment 
policies, and healthcare seeking behaviour, using multilevel models but there might be residual 
confounding. A further limitation of our dataset is that 10% of the patients had missing data for 
exposure to neuraminidase inhibitors and were excluded from the analysis; the characteristics of these 
patients are compared with those with data for neuraminidase inhibitor exposure in appendix pp 26–27; 
these patients were more likely to be older, to have presented to hospital later, less likely to have a 
laboratory confirmed diagnosis, and more likely to be treated with antibiotics. 
The decision to adjust for treatment with antibiotics and corticosteroids was taken after consultation 
with clinical colleagues within the PRIDE study collaboration. This decision results from widespread 
clinical practice to treat patients admitted to hospital with respiratory illness with corticosteroids and 
antibiotics. There is particular uncertainty about the possible effect of corticosteroids on the course of 
severe influenza infection.
33, 34
 Therefore, it was necessary to separate out the possible effects of 
antivirals from these other commonly used treatments. We did not do specific analyses to establish the 
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potential effect of antibiotic or corticosteroid use on mortality, but recognise that these factors both 
warrant further research. Although we were able to adjust for inpatient antibiotics and systemic 
corticosteroid use, we were unable to adjust for pandemic H1N1 vaccination since 35% (8284 of 
23633) of our case series were admitted to hospital before the first availability of vaccine in October, 
2009, and 71% (10 967 of 15 349) of data for vaccination status were missing among those admitted 
after that juncture; however, the available data suggest uptake was no higher than 8% during the study 
period. 
This meta-analysis of individual patient data offers the most rigorous assessment of mortality benefits 
of neuraminidase inhibitor treatment during the 2009–10 pandemic that is likely to be possible using 
retrospective observational data. The greatest likelihood of reduced mortality seems to be attributable 
to treatment started within 2 days of symptom onset. These data offer evidence of the effectiveness of 
neuraminidase inhibitors during the 2009–10 pandemic and are superior to extrapolations from earlier 
data on seasonal influenza; they could retrospectively vindicate prepandemic neuraminidase inhibitor 
antiviral stockpiling decisions made by governments worldwide. Treatment guidance policies should 
increase emphasis on early empirical neuraminidase inhibitor treatment of adult patients admitted to 
hospital after presenting with proven or clinically suspected influenza A H1N1pdm09 virus infection. 
However, most adult patients with suspected or confirmed influenza are not admitted to hospital within 
48 h of illness onset. Therefore, the implications of these findings, although based on patients admitted 
to hospital with influenza A H1N1pdm09, encourage early initiation of neuraminidase inhibitor 
treatment in outpatients who are appreciably unwell with suspected or confirmed influenza, or at 
increased risk of complications, including those with influenza A H3N2 or influenza B. Further studies 
are needed in children to confirm the adequacy of present dose regimens and duration of therapy in 
terms of clinical efficacy. 
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